Expert Rev Neurother. 2004 Jul;4(4):589-99.

Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).

Source

Coastal Neurological Medical Group, 9850 Genesee Avenue, Suite 740, La Jolla, CA 92037, USA. deeesilver@aol.com

Abstract

Levodopa is the main pharmacologic treatment for Parkinson's disease. However, the long-term administration of levodopa is associated with the development of motor complications which can seriously compromise patient function. Increasing evidence indicates that such problems are related to abnormal pulsatile stimulation of striatal dopamine receptors and that treatments providing more continuous stimulation reduce the risk of motor complications. It is possible that administering levodopa with a reversible catechol-O-methyl transferase inhibitor at frequent intervals might reduce the risk of these complications. Stalevo (Orion) combines levodopa, the dopa-decarboxylase inhibitor carbidopa and the catechol-O-methyl transferase inhibitor entacapone in a single tablet. This review provides an overview of the initial clinical experience gained with Stalevo during clinical trials, including several case studies.

PMID:: 15853578; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Molecular Biology Databases

LEVODOPA - HSDB

Supplemental Content

Save items

Related citations in PubMed

Review [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination]. [Neurologia. 2005]
Review [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
Castro A, Valldeoriola F, Linazasoro G, Rodriguez-Oroz MC, Stochi F, Marin C, Rodriguez M, Vaamonde J, Jenner P, Alvarez L, et al. Neurologia. 2005 May; 20(4):180-8.
Review Entacapone/levodopa/carbidopa combination tablet: Stalevo. [Drugs R D. 2003]
Review Entacapone/levodopa/carbidopa combination tablet: Stalevo.
. Drugs R D. 2003; 4(5):310-1.
Levodopa/carbidopa/entacapone in Parkinson's disease. [Expert Rev Neurother. 2009]
Levodopa/carbidopa/entacapone in Parkinson's disease.
Seeberger LC, Hauser RA. Expert Rev Neurother. 2009 Jul; 9(7):929-40.
Levodopa/carbidopa/entacapone (Stalevo). [Neurology. 2004]
Levodopa/carbidopa/entacapone (Stalevo).
Hauser RA. Neurology. 2004 Jan 13; 62(1 Suppl 1):S64-71.
An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. [J Neural Transm. 2005]
An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
Koller W, Guarnieri M, Hubble J, Rabinowicz AL, Silver D. J Neural Transm. 2005 Feb; 112(2):221-30. Epub 2004 Oct 22.

See reviews... See all...

Cited by 1 PubMed Central article

Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. [Neuropsychiatr Dis Treat. 2008]
Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective.
Brooks DJ. Neuropsychiatr Dis Treat. 2008 Feb; 4(1):39-47.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Clinical experience with the novel levodopa formulation entacapone + levodopa + ...
Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
Expert Rev Neurother. 2004 Jul ;4(4):589-99.

PubMed
Do minimally invasive procedures have a place in the treatment of chronic low ba...
Do minimally invasive procedures have a place in the treatment of chronic low back pain?
Expert Rev Neurother. 2004 May ;4(3):479-90.

PubMed
Cluster headache: focus on emerging therapies.
Cluster headache: focus on emerging therapies.
Expert Rev Neurother. 2004 Sep ;4(5):895-907.

PubMed
Interferon-beta1a treatment for multiple sclerosis.
Interferon-beta1a treatment for multiple sclerosis.
Expert Rev Neurother. 2005 Jan ;5(1):25-34.

PubMed
Potential determinants of drug-drug interaction associated dispensing in communi...
Potential determinants of drug-drug interaction associated dispensing in community pharmacies.
Drug Saf. 2005 ;28(5):371-8.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by 1 PubMed Central article

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information